NDA 021307/S-019

**SUPPLEMENT APPROVAL**

Bayer HealthCare LLC
Attention: Dawn Jackman
Senior Associate Director, US Regulatory Affairs
100 Bayer Boulevard
P.O. Box 915
Whippany, NJ 07981-0915

Dear Ms. Jackman:

Please refer to your supplemental new drug application (sNDA) dated and received on April 30, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lotrimin Ultra (butenafine hydrochloride) cream, 1%.

This "Prior Approval" supplemental new drug application provides for the graphic redesign of the carton and immediate container (tube) labels for the Lotrimin Ultra products.

## APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling, described in the table below, and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

| Submitted Draft Labeling | Date Submitted |
|---|---|
| Lotrimin Ultra 12 g carton | July 20, 2021 |
| Lotrimin Ultra 12 g immediate container (tube) | April 30, 2021 |
| Lotrimin Ultra 15 g carton | July 20, 2021 |
| Lotrimin Ultra 15 g immediate container (tube) | April 30, 2021 |
| Lotrimin Ultra 30 g carton | July 20, 2021 |
| Lotrimin Ultra 30 g immediate container (tube) | April 30, 2021 |
| Lotrimin Ultra (jock itch indication) 12 g carton | September 17, 2021 |
| Lotrimin Ultra (jock itch indication) 12 g immediate container (tube) | April 30, 2021 |

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.[1] For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 021307/S-019**." Approval of this submission by FDA is not required before the labeling is used.

## DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.[2] Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

[1] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

[2] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

If you have any questions, contact Xiaoxue Nehrbass, Regulatory Project Manager, at Xiaoxue.Nehrbass@fda.hhs.gov or (301) 796-1486.

Sincerely,

*{See appended electronic signature page}*

Nushin Todd, MD, PhD
Acting Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton and Container Labeling

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/

---

NUSHIN F TODD
10/18/2021 10:15:12 AM